177Lu-前列腺特异性膜抗原-617治疗后的神经系统症状:单中心经验
回顾性分析2022年3月至11月接受177Lu-PSMA-617治疗的185例转移性去势抵抗性前列腺癌患者,50例(27%)出现新发或加重的神经系统症状,最常见为味觉改变(11.9%)和头晕(6%),7例(3.78%)因神经系统症状急诊就诊,无患者因神经系统症状中断治疗。作者认为在治疗前无神经系统症状或中枢神经系统转移的患者中,严重神经系统问题罕见且不太可能需要中断治疗。
要点
- 185例接受177Lu-PSMA-617治疗的患者中,50例(27%)出现新发或加重的神经系统症状。
- 最常见神经系统症状为味觉改变(11.9%,27/185)和头晕(6%,11/185)。
- 7例(3.78%,7/185)因神经系统症状急诊就诊,无患者因神经系统症状中断治疗。
核心结论
- 177Lu-PSMA-617治疗后最常见的神经系统症状为味觉障碍和头晕。
- 在治疗前无神经系统症状或中枢神经系统转移的患者中,作者发现严重神经系统问题罕见且不太可能需要中断治疗。
研究设计与样本
- 回顾性分析2022年3月至2022年11月期间接受177Lu-PSMA-617初始剂量的转移性去势抵抗性前列腺癌患者的临床记录和影像数据。
- 共185例患者接受177Lu-PSMA-617治疗,中位年龄70岁(范围58-90岁),平均随访时间12.04±2.87个月。
- 所有因新发或加重神经系统症状就诊的患者均纳入研究,不论专科预约类型。
主要发现
- 50例患者(27%,50/185)观察到55个新发或加重的神经系统症状。
- 27例(11.9%,27/185)报告味觉改变。
- 11例(6%,11/185)出现无其他明确病因的头晕,其中2例急诊就诊。
- 6例(3.2%,6/185)报告感觉异常;5例(2.7%,5/185)报告头痛,其中3例因症状严重急诊就诊。
- 2例(1.08%,2/185)出现肢体无力;2例(1.08%,2/185)发生缺血性卒中并急诊就诊;1例(0.05%,1/185)出现步态障碍。
关键数值与推荐
- 共7例患者(3.78%,7/185)因神经系统症状急诊就诊。
- 无患者因神经系统症状停止或未能完成177Lu-PSMA-617治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究的随访时间和人群规模可能不足以检测迟发或少见的神经系统症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment with 177Lu-prostate-specific membrane antigen (PSMA)-617 (177Lu-vipivotide tetraxetan [Pluvicto]) prolongs both progression-free and overall survival in advanced PSMA-positive metastatic castration-resistant prostate cancer. Data examining specifically neurologic symptoms after 177Lu-PSMA-617 treatment are scarce. In this study, we aimed to review the neurologic findings in a large cohort of metastatic castration-resistant prostate cancer patients undergoing 177Lu-PSMA-617 therapy. Methods: The clinical records and imaging data of patients who received their initial dose of 177Lu-PSMA-617 between March 2022 and November 2022 were retrospectively reviewed. All patients presenting for medical evaluation, regardless of specific specialty appointments, with new or worsening neurologic symptoms were included in the study. Results: A total of 185 patients underwent 177Lu-PSMA-617 therapy. The median age was 70 y (range, 58-90 y). The mean follow-up time was 12.04 ± 2.87 mo. Fifty-five new or worsening neurologic symptoms were observed in 50 patients (27%, 50/185). Of these, 27 (11.9%, 27/185) reported altered taste. Eleven patients (6%, 11/185) experienced dizziness with no other clear etiology; 2 of these patients were admitted to the emergency department (ED). Paresthesia symptoms were reported in 6 patients (3.2%, 6/185). Five patients (2.7%, 5/185) reported headaches, 3 of these patients were admitted to the ED because of the severity of the symptoms. Two patients (1.08%, 2/185) presented with extremity weakness. Two patients (1.08%, 2/185) had an ischemic stroke and were admitted to the ED. One patient (0.05%, 1/185) exhibited gait disturbances. In total, 7 patients (3.78%, 7/185) were admitted to the ED because of neurologic symptoms. None of the patients discontinued or failed to complete the 177Lu-PSMA-617 therapy because of neurologic symptoms. Conclusion: After 177Lu-PSMA-617 treatment, the most common neurologic symptoms were dysgeusia and dizziness. In this study, our follow-up period and population size might not have been sufficient to detect delayed or uncommon neurologic symptoms. In patients without neurologic symptoms or central nervous system metastases before treatment, we found the development of severe neurologic problems to be rare and unlikely to require discontinuation of treatment.
引用
- Belge Bilgin G, Burkett BJ, Bilgin C, et al. Neurologic Symptoms After 177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. J Nucl Med. 2024. PMID: 39089816. doi:10.2967/jnumed.124.267643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。